{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:21:58Z","timestamp":1790425318022,"version":"4.1.0"},"reference-count":90,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.3892\/ijo.2015.3075","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T03:34:04Z","timestamp":1436326444000},"page":"797-805","source":"Crossref","is-referenced-by-count":56,"title":["The role of inflammation in progression of breast cancer: Friend or foe? (Review)"],"prefix":"10.3892","volume":"47","author":[{"given":"MICHAEL D.","family":"ALLEN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LOUISE J.","family":"JONES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,7,8]]},"reference":[{"key":"key20180107190552_b1-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jnci\/djq101","article-title":"Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis","volume":"102","author":"Kerlikowske","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"key20180107190552_b2-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/bjc.1990.194","article-title":"Duct carcinoma in situ: Predictors of local recurrence and progression in patients treated by surgery alone","volume":"61","author":"Price","year":"1990","journal-title":"Br J Cancer"},{"key":"key20180107190552_b3-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jnci\/djq099","article-title":"Overdiagnosis in cancer","volume":"102","author":"Welch","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"key20180107190552_b4-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1073\/pnas.0931261100","article-title":"Gene expression profiles of human breast cancer progression","volume":"100","author":"Ma","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107190552_b5-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"R87","DOI":"10.1186\/bcr2157","article-title":"Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma","volume":"10","author":"Castro","year":"2008","journal-title":"Breast Cancer Res"},{"key":"key20180107190552_b6-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1155\/2010\/829358","article-title":"Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: A multiplex ligation-dependent probe amplification study","volume":"33","author":"Moelans","year":"2010","journal-title":"Anal Cell Pathol (Amst)"},{"key":"key20180107190552_b7-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jnci\/djt067","article-title":"A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast","volume":"105","author":"Solin","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"key20180107190552_b8-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/path.2803","article-title":"Jekyll and Hyde: The role of the micro-environment on the progression of cancer","volume":"223","author":"Allen","year":"2011","journal-title":"J Pathol"},{"key":"key20180107190552_b9-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0022-5193(82)90388-5","article-title":"How does the extracellular matrix direct gene expression?","volume":"99","author":"Bissell","year":"1982","journal-title":"J Theor Biol"},{"key":"key20180107190552_b10-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0959-8049(92)90134-N","article-title":"Lymphocyte infiltrates as a prognostic variable in female breast cancer","volume":"28A","author":"Aaltomaa","year":"1992","journal-title":"Eur J Cancer"},{"key":"key20180107190552_b11-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(95)91618-0","article-title":"Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation","volume":"346","author":"Stewart","year":"1995","journal-title":"Lancet"},{"key":"key20180107190552_b12-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/(SICI)1096-9896(199702)181:2<200::AID-PATH726>3.0.CO;2-K","article-title":"Angiogenesis and inflammation in ductal carcinoma in situ of the breast","volume":"181","author":"Lee","year":"1997","journal-title":"J Pathol"},{"key":"key20180107190552_b13-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"11238","DOI":"10.1158\/0008-5472.CAN-06-1278","article-title":"Macrophages regulate the angiogenic switch in a mouse model of breast cancer","volume":"66","author":"Lin","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107190552_b14-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/(SICI)1096-9896(199902)187:3<285::AID-PATH238>3.0.CO;2-R","article-title":"Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast","volume":"187","author":"Lee","year":"1999","journal-title":"J Pathol"},{"key":"key20180107190552_b15-ijo-47-03-0797","first-page":"4625","article-title":"Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma","volume":"56","author":"Leek","year":"1996","journal-title":"Cancer Res"},{"key":"key20180107190552_b16-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"key20180107190552_b17-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat Immunol"},{"key":"key20180107190552_b18-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.canlet.2013.01.024","article-title":"Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer","volume":"332","author":"Tang","year":"2013","journal-title":"Cancer Lett"},{"key":"key20180107190552_b19-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"798","DOI":"10.4161\/onci.20427","article-title":"Carcinoma origin dictates differential skewing of monocyte function","volume":"1","author":"B\u00f6gels","year":"2012","journal-title":"OncoImmunology"},{"key":"key20180107190552_b20-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20080108","article-title":"\u2018Re-educating' tumor-associated macrophages by targeting NF-kappaB","volume":"205","author":"Hagemann","year":"2008","journal-title":"J Exp Med"},{"key":"key20180107190552_b21-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1101\/cshperspect.a003285","article-title":"Leukocytes in mammary development and cancer","volume":"3","author":"Coussens","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key20180107190552_b22-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1128\/MCB.12.3.954","article-title":"Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease","volume":"12","author":"Guy","year":"1992","journal-title":"Mol Cell Biol"},{"key":"key20180107190552_b23-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/jnci\/86.2.120","article-title":"Anticolony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis","volume":"86","author":"Scholl","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"key20180107190552_b24-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1084\/jem.193.6.727","article-title":"Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy","volume":"193","author":"Lin","year":"2001","journal-title":"J Exp Med"},{"key":"key20180107190552_b25-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","article-title":"Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy","volume":"1","author":"DeNardo","year":"2011","journal-title":"Cancer Discov"},{"key":"key20180107190552_b26-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2008.03.018","article-title":"The inflammatory chemokines CCL2 and CCL5 in breast cancer","volume":"267","author":"Soria","year":"2008","journal-title":"Cancer Lett"},{"key":"key20180107190552_b27-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2004-03-1109","article-title":"Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues","volume":"104","author":"Murdoch","year":"2004","journal-title":"Blood"},{"key":"key20180107190552_b28-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/bcr1648","article-title":"Oestrogen receptor negative breast cancers exhibit high cytokine content","volume":"9","author":"Chavey","year":"2007","journal-title":"Breast Cancer Res"},{"key":"key20180107190552_b29-ijo-47-03-0797","first-page":"3282","article-title":"Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer","volume":"6","author":"Ueno","year":"2000","journal-title":"Clin Cancer Res"},{"key":"key20180107190552_b30-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/(SICI)1097-0215(19990827)82:5<765::AID-IJC23>3.0.CO;2-F","article-title":"Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1","volume":"82","author":"Goede","year":"1999","journal-title":"Int J Cancer"},{"key":"key20180107190552_b31-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0344-0338(98)80057-5","article-title":"Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer","volume":"194","author":"Valkovi\u0107","year":"1998","journal-title":"Pathol Res Pract"},{"key":"key20180107190552_b32-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-07-0731","article-title":"Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells","volume":"13","author":"Dwyer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107190552_b33-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000077718","article-title":"Monocyte chemoattractant protein-1 serum levels in patients with breast cancer","volume":"25","author":"Lebrecht","year":"2004","journal-title":"Tumour Biol"},{"key":"key20180107190552_b34-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.NNR.0000280655.58266.6c","article-title":"Cytokine comparisons between women with breast cancer and women with a negative breast biopsy","volume":"57","author":"Lyon","year":"2008","journal-title":"Nurs Res"},{"key":"key20180107190552_b35-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"key20180107190552_b36-ijo-47-03-0797","first-page":"4681","article-title":"Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma","volume":"59","author":"Luboshits","year":"1999","journal-title":"Cancer Res"},{"key":"key20180107190552_b37-ijo-47-03-0797","first-page":"285","article-title":"Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer","volume":"7","author":"Niwa","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key20180107190552_b38-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1158\/1078-0432.CCR-06-0074","article-title":"The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients","volume":"12","author":"Yaal-Hahoshen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107190552_b39-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10549-004-5328-3","article-title":"Inhibition of metastasis by inhibition of tumor-derived CCL5","volume":"89","author":"Stormes","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107190552_b40-ijo-47-03-0797","first-page":"8360","article-title":"A chemokine receptor antagonist inhibits experimental breast tumor growth","volume":"63","author":"Robinson","year":"2003","journal-title":"Cancer Res"},{"key":"key20180107190552_b41-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/0008-5472.CAN-11-3917","article-title":"CCR5 antagonist blocks metastasis of basal breast cancer cells","volume":"72","author":"Velasco-Vel\u00e1zquez","year":"2012","journal-title":"Cancer Res"},{"key":"key20180107190552_b42-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature06188","article-title":"Mesenchymal stem cells within tumour stroma promote breast cancer metastasis","volume":"449","author":"Karnoub","year":"2007","journal-title":"Nature"},{"key":"key20180107190552_b43-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2005-01-0428","article-title":"A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3\/STAT1 activation)","volume":"107","author":"Biswas","year":"2006","journal-title":"Blood"},{"key":"key20180107190552_b44-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2353\/ajpath.2010.090908","article-title":"Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer","volume":"176","author":"Jubb","year":"2010","journal-title":"Am J Pathol"},{"key":"key20180107190552_b45-ijo-47-03-0797","first-page":"425","article-title":"Macrophage infiltration and its prognostic implications in breast cancer: The relationship with VEGF expression and microvessel density","volume":"14","author":"Tsutsui","year":"2005","journal-title":"Oncol Rep"},{"key":"key20180107190552_b46-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jclinpath-2011-200355","article-title":"Tumour-infiltrating macrophages and clinical outcome in breast cancer","volume":"65","author":"Mahmoud","year":"2012","journal-title":"J Clin Pathol"},{"key":"key20180107190552_b47-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/(SICI)1097-0142(19970801)80:3<421::AID-CNCR10>3.0.CO;2-Z","article-title":"Expression of interleukin-1beta in human breast carcinoma","volume":"80","author":"Jin","year":"1997","journal-title":"Cancer"},{"key":"key20180107190552_b48-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1158\/0008-5472.CAN-13-1642","article-title":"The emerging role of immunosurveillance in dictating metastatic spread in breast cancer","volume":"73","author":"Slaney","year":"2013","journal-title":"Cancer Res"},{"key":"key20180107190552_b49-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.2830","article-title":"Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape","volume":"18","author":"Bidwell","year":"2012","journal-title":"Nat Med"},{"key":"key20180107190552_b50-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2007.12.004","article-title":"Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis","volume":"13","author":"Yang","year":"2008","journal-title":"Cancer Cell"},{"key":"key20180107190552_b51-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1158\/0008-5472.CAN-07-1882","article-title":"Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma","volume":"67","author":"Melani","year":"2007","journal-title":"Cancer Res"},{"key":"key20180107190552_b52-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/cr.2012.178","article-title":"A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells","volume":"23","author":"Zhang","year":"2013","journal-title":"Cell Res"},{"key":"key20180107190552_b53-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy","volume":"58","author":"Diaz-Montero","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"key20180107190552_b54-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","article-title":"Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer","volume":"190","author":"Yu","year":"2013","journal-title":"J Immunol"},{"key":"key20180107190552_b55-ijo-47-03-0797","first-page":"1463","article-title":"Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer","volume":"12","author":"Chin","year":"1992","journal-title":"Anticancer Res"},{"key":"key20180107190552_b56-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10555-010-9247-y","article-title":"Regulatory T cells and breast cancer: Implications for immuno-pathogenesis","volume":"29","author":"Watanabe","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"key20180107190552_b57-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0020284","article-title":"Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer","volume":"2","author":"Kohrt","year":"2005","journal-title":"PLoS Med"},{"key":"key20180107190552_b58-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"key20180107190552_b59-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1172\/JCI25112","article-title":"Defective regulatory and effector T cell functions in patients with FOXP3 mutations","volume":"116","author":"Bacchetta","year":"2006","journal-title":"J Clin Invest"},{"key":"key20180107190552_b60-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1073\/pnas.0509484103","article-title":"Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development","volume":"103","author":"Gavin","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107190552_b61-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.coi.2007.07.006","article-title":"Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression","volume":"19","author":"Li","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"key20180107190552_b62-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/02841860701233443","article-title":"Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis","volume":"46","author":"Gupta","year":"2007","journal-title":"Acta Oncol"},{"key":"key20180107190552_b63-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180107190552_b64-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2217\/14622416.8.11.1485","article-title":"FOXP3 and breast cancer: Implications for therapy and diagnosis","volume":"8","author":"Liu","year":"2007","journal-title":"Pharmacogenomics"},{"key":"key20180107190552_b65-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107190552_b66-ijo-47-03-0797","first-page":"919","article-title":"Quantitative morphologic assessment of immuno-reactivity in regional lymph nodes of patients with carcinoma of the breast","volume":"140","author":"Wernicke","year":"1975","journal-title":"Surg Gynecol Obstet"},{"key":"key20180107190552_b67-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/030089168607200606","article-title":"Breast tumors: Immunoglobulins in axillary lymph nodes","volume":"72","author":"Urdiales-Viedma","year":"1986","journal-title":"Tumori"},{"key":"key20180107190552_b68-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2249.2003.02259.x","article-title":"Relative paradigms between autoantibodies in lupus and autoantibodies in cancer","volume":"134","author":"Tan","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"key20180107190552_b69-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-011-1620-1","article-title":"The prognostic significance of B lymphocytes in invasive carcinoma of the breast","volume":"132","author":"Mahmoud","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107190552_b70-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1158\/0008-5472.CAN-07-5206","article-title":"The humoral immune system has a key prognostic impact in node-negative breast cancer","volume":"68","author":"Schmidt","year":"2008","journal-title":"Cancer Res"},{"key":"key20180107190552_b71-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2009.06.018","article-title":"CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages","volume":"16","author":"DeNardo","year":"2009","journal-title":"Cancer Cell"},{"key":"key20180107190552_b72-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.cdd.4402255","article-title":"Decoding dangerous death: How cytotoxic chemotherapy invokes inflammation, immunity or nothing at all","volume":"15","author":"van der Most","year":"2008","journal-title":"Cell Death Differ"},{"key":"key20180107190552_b73-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI35180","article-title":"The anticancer immune response: Indispensable for therapeutic success?","volume":"118","author":"Zitvogel","year":"2008","journal-title":"J Clin Invest"},{"key":"key20180107190552_b74-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1158\/0008-5472.CAN-11-0753","article-title":"Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors","volume":"71","author":"Mattarollo","year":"2011","journal-title":"Cancer Res"},{"key":"key20180107190552_b75-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/CCO.0000000000000020","article-title":"Immunotherapeutics for breast cancer","volume":"25","author":"Criscitiello","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"key20180107190552_b76-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107190552_b77-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20180107190552_b78-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180107190552_b79-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"key":"key20180107190552_b80-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JCO.2014.57.6298","article-title":"Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial","volume":"33","author":"Perez","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20180107190552_b81-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2407-8-57","article-title":"FOXP3+ Tregs and B7-H1+\/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy","volume":"8","author":"Ghebeh","year":"2008","journal-title":"BMC Cancer"},{"key":"key20180107190552_b82-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10549-013-2581-3","article-title":"The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer","volume":"139","author":"Muenst","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107190552_b83-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"key20180107190552_b84-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"key20180107190552_b85-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"key20180107190552_b86-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with meta-static melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180107190552_b87-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180107190552_b88-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1158\/1078-0432.CCR-10-0505","article-title":"Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells","volume":"16","author":"Vonderheide","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20180107190552_b89-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Stagg","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107190552_b90-ijo-47-03-0797","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri3192","article-title":"The storm has cleared: Lessons from the CD28 super-agonist TGN1412 trial","volume":"12","author":"H\u00fcnig","year":"2012","journal-title":"Nat Rev Immunol"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2015.3075\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T22:38:21Z","timestamp":1566945501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2015.3075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,8]]},"references-count":90,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,7,8]]},"published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.3892\/ijo.2015.3075"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2015.3075","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,8]]}}}